EPHA6: IHC Expression in Cancer and Radioligand Target Profile
EPHA6, EPH receptor A6, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, EPHA6 staining is highest in colorectal cancer (91% of samples positive), endometrial cancer (91% of samples positive) and glioma (82% of samples positive). Published literature suggests EPHA6 does not readily internalize, so radionuclide retention may rely on surface binding. Clinical status: FDA-approved drug (any modality).
Is EPHA6 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze EPHA6 freeIs EPHA6 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in colorectal cancer, 91% of samples positive.
- ❌ Internalization: Reported not to internalize.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
EPHA6 IHC staining by cancer type
Protein expression of EPHA6 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 0.76 | High | 91% |
| Endometrial Cancer | 0.67 | High | 91% |
| Glioma | 0.48 | Medium | 82% |
| Liver Cancer | 0.44 | Medium | 67% |
| Prostate Cancer | 0.42 | Medium | 100% |
| Thyroid Cancer | 0.42 | Medium | 100% |
| Breast Cancer | 0.42 | Medium | 75% |
| Cervical Cancer | 0.42 | Medium | 67% |
| Head and Neck Cancer | 0.33 | Medium | 100% |
| Bladder Cancer | 0.33 | Medium | 75% |
| Gastric Cancer | 0.33 | Medium | 67% |
| Neuroendocrine Tumors | 0.25 | Medium | 75% |
| Ovarian Cancer | 0.24 | Medium | 46% |
| Testicular Cancer | 0.21 | Medium | 64% |
| Lung Cancer | 0.21 | Medium | 36% |
| Skin Cancer | 0.14 | Low | 42% |
| Lymphoma | 0.11 | Low | 33% |
| Pancreatic Cancer | 0.11 | Low | 33% |
| Melanoma | 0.08 | Low | 25% |
| Kidney Cancer | 0.08 | Low | 25% |
Is EPHA6 internalized?
No. The abstract mentions that Odin regulates endocytosis, degradation, and stability of EphA receptors, but there is no direct evidence that EPHA6 itself undergoes internalization or endocytosis upon binding.
Sources: PMID 35732074. AI-extracted from abstracts, so verify before citing.
EPHA6 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for EPHA6 yet. Search ClinicalTrials.gov for EPHA6 trials.
EPHA6 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EPHA6 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
EPHA6 gene essentiality (DepMap)
CRISPR knockout effect across 1245 cancer cell lines: 0.07 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EGFR · FAP · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how EPHA6 ranks against 15,000 targets for your indication.
Analyze EPHA6 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.